Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
Send Cancel

Human anti-cancer drugs could help Tasmanian devils
Tasmanian devils are considered endangered as a result of devil facial tumour 1.
RTKs have ‘an important role’ in sustaining transmissible cancers

Key drugs used to treat cancer in humans may also be useful in the fight against transmissible cancers in Tasmanian devils.

This is according to a new study by the University of Cambridge, which found that certain drugs used in humans were able to efficiently stop the growth of devil cancer cells in the lab.

The research, published in the journal Cancer Cell, shows that molecules known as receptor tyrosine kinases (RTKs) have an important role to play in sustaining the growth and survival of transmissible cancers in devils. Drugs targeting RTKs have already been developed for human cancers.

Tasmanian devils are considered endangered as a result of devil facial tumour 1 (DFT1), which is passed between animals through biting and causes disfiguring facial tumours. Usually fatal, DFT1 has spread throughout Tasmania since it was first seen in 1996, causing significant declines in devil populations.

Routine diagnostic screening in 2014 uncovered a second transmissible cancer in the species. With the naked eye, facial tumours caused by devil facial tumour 2 (DFT2) cannot be distinguished from those caused by DFT1, but analysis has shown they differ at a biological level.

Cambridge researchers found striking similarities between the two cancer types; in terms of genetics, tissues of origin, the way in which the cancer cells mutate and possible drug targets.

First author Dr Elizabeth Murchison said: “The story of Tasmanian devils in recent years has been a very concerning one. This study gives us optimism that anti-cancer drugs that are already in use in humans may offer a chance to assist with conservation efforts for this iconic animal.”

Become a member or log in to add this story to your CPD history

Wildlife presenter to deliver keynote speech at BVA Congress

News Story 1
 The BVA has confirmed wildlife presenter Mike Dilger will deliver the keynote speech at this yearís congress. Mike is known as ĎBritainís most diseased maní, having contracted a number of exotic diseases on his travels, including malaria, bilharzia and leishmaniasis. His talk, ĎMy diseases and other animalsí, promises to be an amusing and inspiring lecture on his travels in the tropics and his thoughts on how the mass media is influencing human engagement with wildlife and nature. The lecture will take place at 1pm on 16 November, in the BVA Congress Theatre at Londonís ExCeL. 

Click here for more...
News Shorts
Vet school runs event for aspiring vets and nurses

Bristol Veterinary School is hosting an event for aspiring vets and vet nurses, to allow them to experience life as a student and find out what itís like to work in veterinary medicine. The one-day event, called VetQuest, will be held at the Langford Campus and includes a tour, talks on admissions and work experience, and the chance to take part in practical sessions. Taking place on Saturday 27 October, the event is primarily aimed at 11-12 year olds and costs £50, including lunch. There are a limited number of subsidised tickets for £10. To book, visit VetQuest 2018